title: The role of molecular biomarkers for predicting adjacent breast cancer of Atypical Ductal Hyperplasia diagnosed on core biopsy.
abstract: BACKGROUND
  Atypical Ductal Hyperplasia (ADH) is a disease of the proliferative breast lesion characterized with atypia and when diagnosed on core needle biopsy (CNB), excisional biopsy is the current management to exclude adjacent cancer, which may found 10 to 20%.
  
  
  OBJECTIVE
  The purpose of the study is to investigate the role of biomarkers on surgical decision after the diagnosis of ADH on CNB.
  
  
  METHODS
  Patients with pure ADH on core biopsy were retrospectively selected, and categorized according to final pathology after excision into three groups: Group I (n: 39) ADH; Group II (n: 27) ductal carcinoma in situ (DCIS), and Group III (n: 9) invasive cancer (IC). Immunohistochemical analyses were performed using biomarkers MUC1, Ki67, Cyclin B1, and Cyclin D1.
  
  
  RESULTS
  Only Cyclin D1 was significant in between group analysis by one-way ANOVA (64.74, 49.44, and 51.11, respectively; p= 0.01). However when appropriate cut-off levels (2%-50%) were used for each biomarkers using X2 test, no statistical significance was found.
  
  
  CONCLUSIONS
  MUC1, Ki67, Cyclin B, and Cyclin D1have failed to predict adjacent cancer on core biopsy specimens with ADH. Further surgery is warranted for all ADH cases diagnosed on core biopsies until a new predictor is identified.
authors: Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.|Department of General Surgery, University of Ondokuz Mayıs Faculty of Medicine, Samsun, Turkey.
authors: Ayfer Kamali
authors: AK
authors: Polat
authors: Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.
authors: Atilla
authors: A
authors: Soran
authors: Department of Pathology - Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, PA, USA.
authors: Amal
authors: A
authors: Kanbour-Shakir
authors: Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.
authors: Ebru
authors: E
authors: Menekse
authors: Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.
authors: Fatih
authors: F
authors: Levent Balci
authors: Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.
authors: Ronald
authors: R
authors: Johnson
mesh_terms: D015415:Biomarkers; D062005:Biopsy, Large-Core Needle; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000378:metabolism* / Q000601:surgery; D000066491:Clinical Decision-Making; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D015415:Biomarkers
keywords: Atypical ductal hyperplasia; Ki67; MUC1; biomarker; breast cancer; cyclin